Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Brandon Jarosin

Physician Assistant El Cajon, CA Physician Assistant

NPI 1104591627 CMS profile 11071074

1380 El Cajon Blvd Ste 100, El Cajon, CA 92020

Open in the dashboard

General payments

$16,818

845 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Brandon Jarosin of El Cajon, CA is reported in the CMS Open Payments database as having received $16,818 across 845 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,270 146
2024 General $3,955 225
2023 General $4,220 216
2022 General $3,825 184
2021 General $1,548 74

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Brandon Jarosin
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Brandon Jarosin were reported at $3,270. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Brandon Jarosin Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $1,548 $132 $37–$438 $132
2022 $3,825 $155 $48–$522 $149
2023 $4,220 $167 $52–$557 $160
2024 $3,955 $178 $55–$600 $164
2025 $3,270 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Novartis Pharmaceuticals Corporation $1,720 107 payments
  2. Edwards Lifesciences Corporation $1,700 18 payments
  3. CVRx, Inc. $1,502 57 payments
  4. Amgen Inc. $1,097 47 payments
  5. Merck Sharp & Dohme Corporation $1,053 48 payments
  6. Actelion Pharmaceuticals US, Inc. $921 84 payments
  7. Janssen Pharmaceuticals, Inc $865 51 payments
  8. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $801 48 payments
  9. Bayer HealthCare Pharmaceuticals Inc. $722 36 payments
  10. Esperion Therapeutics, Inc. $534 53 payments
  11. Other $5,903 296 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $16,781 842 payments
  2. Education $37 3 payments
Products named General payments · program years 2021–2025
  1. Barostim Neo System $1,502 57 payments
  2. VERQUVO $1,066 49 payments
  3. Repatha $1,062 45 payments
  4. LEQVIO $968 60 payments
  5. SAPIEN 3 Ultra RESILIA $953 8 payments
  6. OPSUMIT $915 83 payments
  7. UPTRAVI $914 83 payments
  8. XARELTO $865 51 payments
  9. LifeVest $801 48 payments
  10. Kerendia $722 36 payments
  11. Other $8,686 439 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

845 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record